$AURA

Citizens maintained an Outperform rating and $15.00 price target for Aura Biosciences (AURA), citing progress in its Phase 3 CoMpass trial. The stock, trading at $7.66, has 100% upside potential. Citizens estimates a 60% trial success probability. H.C. Wainwright lowered its target to $18 but kept a Buy rating. AURA has more cash than debt, supporting its clinical programs. The company plans investor updates on choroidal melanoma and expects trial data in late 2027.

Aura Biosciences (AURA) reported Q3 2026 results, highlighting progress in its Phase 3 CoMpass trial for early choroidal melanoma. The trial has enrolled 108 participants, with topline results expected in late 2027. The company expects its cash to last into 2029. AURA's stock closed at $6.56, up 3.47%.

Aura Biosciences reported a wider net loss in Q3 2026, with increased R&D and G&A expenses offsetting higher interest income. The loss per share narrowed to $0.29. The CoMpass trial enrollment is complete, and topline data is expected in 2H 2027. The company also reported interim data for NMIBC treatment and completed a restructuring.

Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing des

Aura Investments (TASE: AURA) is acquiring a 55% stake in Bait Bakfar (TASE: BKFR) for NIS 935 million, valuing the assisted living chain at NIS 1.7 billion. Aura plans a tender offer for the remaining shares, with a 28% premium over BKFR's current share price. The deal includes cash and Aura shares, valuing Aura at NIS 5.5 billion.

Aura Minerals (AUGO) agreed to acquire Newco, which holds mining fleets and leases for its Brazilian operations, for R$612M (~$118M). The company expects to reduce AISC by $150–$200/oz from 2027, pending closing conditions. The deal aims to cut costs and improve scale.

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

H.C. Wainwright cut its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24 and kept a Buy rating. The stock trades at about $8.04. The firm cited Phase 3 CoMpass enrollment completion in June 2026 (108 patients) and expects topline data in 2H 2027, while shifting capital toward ocular oncology.

Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on develo

Aura Biosciences, Inc. (AURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 5, 2026, Aura Biosciences, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of June 12, 2026, the record date for the Special Meeting, there were 103,436,416 shares of